Clinical efficacy and safety of MP-AzeFlu for the treatment of allergic rhinitis: a meta-analysis

xlomafota13 shared this article with you from Inoreader Clinical efficacy and safety of MP-AzeFlu for the treatment of allergic rhinitis: a meta-analysis Via http://link.springer.com/journal/405,European archives of oto-rhino-laryngology,The European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino Eur Arch Otorhinolaryngol. 2021 Aug 20. doi: 10.1007/s00405-021-07048-1. Online ahead of print. ABSTRACT OBJECTIVE: MP-AzeFlu is a novel option for therapy of allergic rhinitis (AR). The purpose of our study was to assess the safety and efficacy of MP-AzeFlu for the treatment of allergic rhinitis, compared to placebo and azelastine monotherapy. METHODS: The PubMed, MEDLINE, EMBASE and Cochrane databases were comprehensively searched for all published randomized controlled trials (RCTs) of using MP-AzeFlu nasal spray on July 26, 2019. In these studies, we selected patients with clinical symptom scores. The heterogeneity of the included studies was assessed by I2. RESULTS: Among the 336 citations retrieved, 6 articles with over 6000 patients were finally included in the meta-analysis. The results of meta-analysis revealed that MP-AzeFlu was superior to placebo ( - 2.43 [95%CI, - 2.73 to - 2.14], P < 0.00001) and azelastine ( - 1.27 [95% CI, - 1.57 to - 0.97], P < 0.00001) in reflective total nasal symptom score. In the MP-AzeFlu group, the instantaneous total nasal symptom score ( - 2.56 [95% CI, - 3.02 to - 2.10], P < 0.00001) and the reflective total ocular symptom score ( - 1.22 [95% CI, - 1.57 to - 0.87], P < 0.00001) were significantly reduced compared to the placebo group. CONCLUSION: MP-AzeFlu is as safe and mild as placebo and azelastine, which also is associated with symptom relief and the improvement of quality of life in AR patients. MP-AzeFlu can provide better clinical benefits than two currently available first-line intranasal therapies. It is an ideal therapy for AR patients. PMID:34415405 | DOI:10.1007/s00405-021-07048-1 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.